Actos—pioglitazone—is one of the best-selling drugs in the United States, used in the treatment of Type 2 diabetes. Actos gained FDA approval some thirteen years ago, and despite numerous reports of adverse health symptoms linked to Actos.
Actos is a prescription drug manufactured by Takeda, a Japanese pharmaceutical corporation, over thirteen years ago and is used in the treatment of Type 2 diabetes. While there were many adverse health issues reported among users of Actos
Continuing from part one which details the particulars of the pending Actos lawsuits, part two will talk about the MDL case as well as case law which may pertain to Actos suits. The discussion at a recent attorney’s conference regarding Actos litigation discussed the highlights of the MDL Actos case.
The drug Actos, also known as pioglitazone, has recently come under fire due to studies showing a slight increased risk of bladder cancer in those taking high doses of the drug or those who have taken Actos for longer than two years. Manufactured by Takeda Pharmaceuticals of Japan, the drug has shown huge gains in popularity in the past few years as it quickly replaced the drug Avandia which suffered under claims of increased risk of heart attack and death.